TY - JOUR
T1 - Data Sharing Under the General Data Protection Regulation
T2 - Time to Harmonize Law and Research Ethics?
AU - Vlahou, Antonia
AU - Hallinan, Dara
AU - Apweiler, Rolf
AU - Argiles, Angel
AU - Beige, Joachim
AU - Benigni, Ariela
AU - Bischoff, Rainer
AU - Black, Peter C.
AU - Boehm, Franziska
AU - Céraline, Jocelyn
AU - Chrousos, George P.
AU - Delles, Christian
AU - Evenepoel, Pieter
AU - Fridolin, Ivo
AU - Glorieux, Griet
AU - Van Gool, Alain J.
AU - Heidegger, Isabel
AU - Ioannidis, John P.A.
AU - Jankowski, Joachim
AU - Jankowski, Vera
AU - Jeronimo, Carmen
AU - Kamat, Ashish M.
AU - Masereeuw, Rosalinde
AU - Mayer, Gert
AU - Mischak, Harald
AU - Ortiz, Alberto
AU - Remuzzi, Giuseppe
AU - Rossing, Peter
AU - Schanstra, Joost P.
AU - Schmitz-Dräger, Bernd J.
AU - Spasovski, Goce
AU - Staessen, Jan A.
AU - Stamatialis, Dimitrios
AU - Stenvinkel, Peter
AU - Wanner, Christoph
AU - Williams, Stephen B.
AU - Zannad, Faiez
AU - Zoccali, Carmine
AU - Vanholder, Raymond
N1 - Publisher Copyright:
© 2021 The Authors.
PY - 2021/4/1
Y1 - 2021/4/1
N2 - The General Data Protection Regulation (GDPR) became binding law in the European Union Member States in 2018, as a step toward harmonizing personal data protection legislation in the European Union. The Regulation governs almost all types of personal data processing, hence, also, those pertaining to biomedical research. The purpose of this article is to highlight the main practical issues related to data and biological sample sharing that biomedical researchers face regularly, and to specify how these are addressed in the context of GDPR, after consulting with ethics/legal experts. We identify areas in which clarifications of the GDPR are needed, particularly those related to consent requirements by study participants. Amendments should target the following: (1) restricting exceptions based on national laws and increasing harmonization, (2) confirming the concept of broad consent, and (3) defining a roadmap for secondary use of data. These changes will be achieved by acknowledged learned societies in the field taking the lead in preparing a document giving guidance for the optimal interpretation of the GDPR, which will be finalized following a period of commenting by a broad multistakeholder audience. In parallel, promoting engagement and education of the public in the relevant issues (such as different consent types or residual risk for re-identification), on both local/national and international levels, is considered critical for advancement. We hope that this article will open this broad discussion involving all major stakeholders, toward optimizing the GDPR and allowing a harmonized transnational research approach.
AB - The General Data Protection Regulation (GDPR) became binding law in the European Union Member States in 2018, as a step toward harmonizing personal data protection legislation in the European Union. The Regulation governs almost all types of personal data processing, hence, also, those pertaining to biomedical research. The purpose of this article is to highlight the main practical issues related to data and biological sample sharing that biomedical researchers face regularly, and to specify how these are addressed in the context of GDPR, after consulting with ethics/legal experts. We identify areas in which clarifications of the GDPR are needed, particularly those related to consent requirements by study participants. Amendments should target the following: (1) restricting exceptions based on national laws and increasing harmonization, (2) confirming the concept of broad consent, and (3) defining a roadmap for secondary use of data. These changes will be achieved by acknowledged learned societies in the field taking the lead in preparing a document giving guidance for the optimal interpretation of the GDPR, which will be finalized following a period of commenting by a broad multistakeholder audience. In parallel, promoting engagement and education of the public in the relevant issues (such as different consent types or residual risk for re-identification), on both local/national and international levels, is considered critical for advancement. We hope that this article will open this broad discussion involving all major stakeholders, toward optimizing the GDPR and allowing a harmonized transnational research approach.
KW - Ethics, Research
KW - Government Regulation
KW - biomedical research
KW - data management
KW - informed consent
UR - http://www.scopus.com/inward/record.url?scp=85102905901&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102905901&partnerID=8YFLogxK
U2 - 10.1161/HYPERTENSIONAHA.120.16340
DO - 10.1161/HYPERTENSIONAHA.120.16340
M3 - Review article
C2 - 33583200
AN - SCOPUS:85102905901
SN - 0194-911X
VL - 77
SP - 1029
EP - 1035
JO - Hypertension
JF - Hypertension
IS - 4
ER -